These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 24912810)
1. MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice. Fang F; Ma J; Ni W; Wang F; Sun X; Li Y; Li Q; Xie F; Wang J; Zhai R; Liu Z; Gao S; Tai G Mol Med Rep; 2014 Aug; 10(2):1056-64. PubMed ID: 24912810 [TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623 [TBL] [Abstract][Full Text] [Related]
3. Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine. Hu B; Wang J; Guo Y; Chen T; Ni W; Yuan H; Zhang N; Xie F; Tai G Int Immunopharmacol; 2016 Apr; 33():108-18. PubMed ID: 26896668 [TBL] [Abstract][Full Text] [Related]
4. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model. Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233 [TBL] [Abstract][Full Text] [Related]
5. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192 [TBL] [Abstract][Full Text] [Related]
6. Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF. Yuan S; Shi C; Han W; Ling R; Li N; Wang T Eur J Cancer Prev; 2009 Sep; 18(5):416-23. PubMed ID: 19550341 [TBL] [Abstract][Full Text] [Related]
7. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity. Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287 [TBL] [Abstract][Full Text] [Related]
8. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene. Choi DH; Woo JK; Choi Y; Seo HS; Kim CW Mol Med Rep; 2011; 4(5):885-90. PubMed ID: 21725596 [TBL] [Abstract][Full Text] [Related]
9. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine. Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188 [TBL] [Abstract][Full Text] [Related]
10. CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity. Jie J; Zhang Y; Zhou H; Zhai X; Zhang N; Yuan H; Ni W; Tai G Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558459 [TBL] [Abstract][Full Text] [Related]
11. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth. Yuan S; Shi C; Lv Y; Wang T; Wang H; Han W Cancer Biother Radiopharm; 2009 Oct; 24(5):607-13. PubMed ID: 19877891 [TBL] [Abstract][Full Text] [Related]
12. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats. Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759 [TBL] [Abstract][Full Text] [Related]
13. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2. He J; Shen D; O'Donnell MA; Chang HR Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014 [TBL] [Abstract][Full Text] [Related]
14. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167 [TBL] [Abstract][Full Text] [Related]
15. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses. Trujillo-Vargas CM; Mayer KD; Bickert T; Palmetshofer A; Grunewald S; Ramirez-Pineda JR; Polte T; Hansen G; Wohlleben G; Erb KJ Clin Exp Allergy; 2005 Aug; 35(8):1003-13. PubMed ID: 16120081 [TBL] [Abstract][Full Text] [Related]
16. Recombinant BCG coexpressing Ag85B, ESAT-6 and Rv3620c elicits specific Th1 immune responses in C57BL/6 mice. Yang E; Lu Y; Xu Y; Liang Q; Wang C; Wang H; Shen H Microb Pathog; 2014; 69-70():53-9. PubMed ID: 24726737 [TBL] [Abstract][Full Text] [Related]
17. Skewing of the Th1/Th2 responses in mice due to variation in the level of expression of an antigen in a recombinant BCG system. Dhar N; Rao V; Tyagi AK Immunol Lett; 2003 Sep; 88(3):175-84. PubMed ID: 12941476 [TBL] [Abstract][Full Text] [Related]
18. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Barratt-Boyes SM; Vlad A; Finn OJ Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099 [TBL] [Abstract][Full Text] [Related]
19. Immune responses induced by heterologous boosting of recombinant bacillus Calmette-Guerin with Ag85B-ESAT6 fusion protein in levamisole-based adjuvant. You Q; Wu Y; Jiang D; Wu Y; Wang C; Wei W; Yu X; Zhang X; Kong W; Jiang C Immunol Invest; 2012; 41(4):412-28. PubMed ID: 22360290 [TBL] [Abstract][Full Text] [Related]
20. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy. Yuan S; Shi C; Liu L; Han W Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]